Pharmacophore modeling for ADME.

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Pharmacology

Background:

• Late-stage drug candidate failure frequently stems from pharmacokinetic issues identified during clinical trials.
• There is a growing consensus on integrating pharmacokinetic assessments earlier in the drug discovery pipeline.
• Computer-aided design (CAD) offers tools for developing predictive pharmacokinetic models.

Purpose of the Study:

• To review existing pharmacophore models for cytochrome P450 (CYP) enzymes and related metabolic proteins.
• To highlight challenges in developing single, highly predictive pharmacophore models due to enzyme flexibility and multiple binding sites.
• To propose a novel strategy for early-stage prediction of drug metabolism using multiple, diverse pharmacophore models.

Main Methods:

• Comprehensive review of published pharmacophore models for key CYP isoenzymes (CYP1A2, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4).
• Inclusion of models for CYP19 (aromatase), CYP51 (14.α-lanosterol demethylase), PXR (pregnane X-receptor), and human intrinsic clearance.
• Schematic representation of models to visualize similarities and differences.

Main Results:

• Significant variability exists among pharmacophore models developed by different research groups.
• The inherent flexibility and large active sites of CYP enzymes contribute to challenges in creating single predictive models.
• Multiple binding modes within CYP enzymes necessitate diverse modeling approaches.

Conclusions:

• A single pharmacophore model is insufficient for accurately predicting drug interactions with CYP enzymes.
• Propose developing multiple, diverse pharmacophore models for each identified binding mode.
• Advocate for using a battery of models to generate a P450 interaction profile for early-stage drug candidates, reducing development costs.